Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data
Open Access
- 30 December 2009
- journal article
- review article
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 312
- https://doi.org/10.1186/1475-2875-8-312
Abstract
The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The immunologic basis for how the vaccine protects against both infection and disease remains uncertain. It is, therefore, timely to review the information currently available about the vaccine with regard to how it impacts the human-Plasmodium falciparum host-pathogen relationship. In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.Keywords
This publication has 66 references indexed in Scilit:
- Plasmodium falciparum-Specific Cellular Immune Responses after Immunization with the RTS,S/AS02D Candidate Malaria Vaccine in Infants Living in an Area of High Endemicity in MozambiqueInfection and Immunity, 2009
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of ProtectionThe Journal of Infectious Diseases, 2009
- Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican ChildrenThe Journal of Infectious Diseases, 2009
- Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of ExposureInfection and Immunity, 2009
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeNew England Journal of Medicine, 2008
- Protective CD8+ T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune responseImmunological Reviews, 2008
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine AloneInfection and Immunity, 2007
- A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite ChallengeInfection and Immunity, 2006
- Common West African HLA antigens are associated with protection from severe malariaNature, 1991